Anil Chauhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anil Chauhan has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Meenu Singh
AIIMS, Rishikesh
16 shared publications - Amit Agarwal
Department of Telemedicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India
10 shared publications - Nishant Jaiswal
Health Economics and Health Technology Assessment, School of Health and Wellbeing, University of Glasgow, Glasgow, UK
8 shared publications Meenu Singh
Department of Pediatrics, Postgraduate Institute of Medical Research and Education, Chandigarh, India
6 shared publicationsPranita Pradhan
Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
5 shared publicationsManvi Singh
Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
4 shared publications
Latest Publications
- 10 November 2025
- Published by SAGE Publications in The Cleft Palate Craniofacial Journal
- Vol. 63 (9) , 2755-2768
Effectiveness of Presurgical Orthopedic Interventions in Infants With Unilateral Cleft Lip and Palate: A Systematic Review and Network Meta-Analysis
Objective: To assess the effects of different Presurgical Orthopedic (PSO) appliances on alignment of alveolar segments and nasal morphology in infants with unilateral cleft lip and palate. Methodology: A comprehensive electronic search was performed across health science databases up to March 23, 2025, supplemented by manual searching, gray literature, and unpublished material, following PRISMA guidelines. Study quality was evaluated using ROBINS-I (Risk Of Bias In Nonrandomized Studies—of Interventions) and Cochrane RoB 2 (risk-of-bias) tools. Included studies were randomized controlled trials (RCTs) or non-RCTs involving infants with unilateral cleft lip and palate treated with PSO techniques, focusing on alveolar segment alignment and nasal morphology. Quantitative data were analyzed through a Frequentist network meta-analysis (NMA) using Python and meta-insight software to compare the effectiveness of different PSO interventions. Results: Twenty-one studies (9 RCTs, 8 prospective, and 4 retrospective) were included. The network meta-analysis revealed that Grayson's NAM achieved the greatest reduction in alveolar gap width [– 10.00 (95% confidence interval (CI) −12.22; −7.78)]mm while the Figueroa presurgical nasoalveolar molding technique showed the most improvement in columella angle (17.50, 95% CI [6.61, 28.39]) degrees followed by Dynacleft with Nasal elevator [15.34, 95% CI (−0.07, 30.75)] degrees from the baseline. Conclusion: All PSO techniques demonstrated improvements in alveolar cleft width reduction and columella angle enhancement, with the Grayson technique for alveolar cleft width reduction and the Figueroa technique and Dynacleft with Nasal elevator technique for columella angle, being more effective than the others without being statistically different. PROSPERO Registration number: CRD42025632490
- 10 November 2025
- Published by SAGE Publications in The Cleft Palate Craniofacial Journal
- Vol. 63 (9) , 2755-2768
Effectiveness of Presurgical Orthopedic Interventions in Infants With Unilateral Cleft Lip and Palate: A Systematic Review and Network Meta-Analysis
Objective: To assess the effects of different Presurgical Orthopedic (PSO) appliances on alignment of alveolar segments and nasal morphology in infants with unilateral cleft lip and palate. Methodology: A comprehensive electronic search was performed across health science databases up to March 23, 2025, supplemented by manual searching, gray literature, and unpublished material, following PRISMA guidelines. Study quality was evaluated using ROBINS-I (Risk Of Bias In Nonrandomized Studies—of Interventions) and Cochrane RoB 2 (risk-of-bias) tools. Included studies were randomized controlled trials (RCTs) or non-RCTs involving infants with unilateral cleft lip and palate treated with PSO techniques, focusing on alveolar segment alignment and nasal morphology. Quantitative data were analyzed through a Frequentist network meta-analysis (NMA) using Python and meta-insight software to compare the effectiveness of different PSO interventions. Results: Twenty-one studies (9 RCTs, 8 prospective, and 4 retrospective) were included. The network meta-analysis revealed that Grayson's NAM achieved the greatest reduction in alveolar gap width [– 10.00 (95% confidence interval (CI) −12.22; −7.78)]mm while the Figueroa presurgical nasoalveolar molding technique showed the most improvement in columella angle (17.50, 95% CI [6.61, 28.39]) degrees followed by Dynacleft with Nasal elevator [15.34, 95% CI (−0.07, 30.75)] degrees from the baseline. Conclusion: All PSO techniques demonstrated improvements in alveolar cleft width reduction and columella angle enhancement, with the Grayson technique for alveolar cleft width reduction and the Figueroa technique and Dynacleft with Nasal elevator technique for columella angle, being more effective than the others without being statistically different. PROSPERO Registration number: CRD42025632490
- Open Access
- 5 July 2024
- Published by Georg Thieme Verlag KG in International Archives of Otorhinolaryngology
- Vol. 28 (03) , e552-e558
Economic Burden of Otitis Media Globally and an Overview of the Current Scenario to Alleviate the Disease Burden: A Systematic Review
Introduction The prevalence of otitis media (OM) is substantial all over the world. Epidemiological data related to the economic burden of OM globally is minimal. The present systematic review was undertaken to estimate the economic burden of this disease in various parts of the world. Objectives An extensive literature search was done using PRISMA guidelines to identify relevant studies that estimated the economic burden of OM in monetary terms. The databases searched were PubMed Central, Ovid, and Embase. The cost estimation was done for one specific year and then compared considering the inflation rate. Data Synthesis The literature search led to the inclusion of 10 studies. The studies evaluated direct and indirect costs in monetary terms. Direct costs (health system and patient perspective) ranged from USD (United States Dollar) 122.64 (Netherlands) to USD 633.6 (USA) per episode of OM. Looking at only the patient perspective, the costs ranged from USD 19.32 (Oman) to USD 80.5 (Saudi Arabia). The total costs (direct and indirect) ranged from USD 232.7 to USD 977 (UK) per episode of OM. The economic burden per year was highest in the USA (USD 5 billion). The incidence of OM episodes was found more in children < 5 years old. Introduction of pneumococcal conjugate vaccines decreased the incidence in children and now the prevalence in adults is of concern. Conclusion The economic burden of OM is relatively high globally and addressing this public health burden is important. Approaches for the prevention, diagnosis, and treatment should be undertaken by the health system to alleviate this disease burden.
- 5 July 2024
- Published by Georg Thieme Verlag KG in International Archives of Otorhinolaryngology
- Vol. 28 (03) , e552-e558
Open AccessEconomic Burden of Otitis Media Globally and an Overview of the Current Scenario to Alleviate the Disease Burden: A Systematic Review
Introduction The prevalence of otitis media (OM) is substantial all over the world. Epidemiological data related to the economic burden of OM globally is minimal. The present systematic review was undertaken to estimate the economic burden of this disease in various parts of the world. Objectives An extensive literature search was done using PRISMA guidelines to identify relevant studies that estimated the economic burden of OM in monetary terms. The databases searched were PubMed Central, Ovid, and Embase. The cost estimation was done for one specific year and then compared considering the inflation rate. Data Synthesis The literature search led to the inclusion of 10 studies. The studies evaluated direct and indirect costs in monetary terms. Direct costs (health system and patient perspective) ranged from USD (United States Dollar) 122.64 (Netherlands) to USD 633.6 (USA) per episode of OM. Looking at only the patient perspective, the costs ranged from USD 19.32 (Oman) to USD 80.5 (Saudi Arabia). The total costs (direct and indirect) ranged from USD 232.7 to USD 977 (UK) per episode of OM. The economic burden per year was highest in the USA (USD 5 billion). The incidence of OM episodes was found more in children < 5 years old. Introduction of pneumococcal conjugate vaccines decreased the incidence in children and now the prevalence in adults is of concern. Conclusion The economic burden of OM is relatively high globally and addressing this public health burden is important. Approaches for the prevention, diagnosis, and treatment should be undertaken by the health system to alleviate this disease burden.
- 16 January 2022
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 89 (6) , 570-578
Burden of Attention Deficit Hyperactivity Disorder (ADHD) in Indian Children: A Systematic Review and Meta-Analysis
Objective To determine the pooled prevalence of attention deficit hyperactivity disorder (ADHD) in Indian children. Methods The searching of published literature was conducted in different databases (PubMed, Ovid SP, and EMBASE). The authors also tried to acquire information from the unpublished literature about the prevalence of ADHD. A screening was done to include eligible original studies, community or school-based, cross-sectional or cohort, reporting the prevalence of ADHD in children aged ≤ 18 y in India. Retrieved data were analyzed using STATA MP12 (Texas College station). Results Of 729 studies retrieved by searching different databases, 183 studies were removed as duplicates, and 546 titles and abstracts were screened. After screening, 19 studies were included for quantitative analysis. Subgroup analysis was conducted with respect to their setting (school-based/community-based). Fifteen studies performed in a school-based setting showed 75.1 (95% CI 56.0–94.1) pooled prevalence of ADHD per 1000 children of 4–19 y of age. In community-based settings, the pooled prevalence per 1000 children surveyed was 18.6 (95% CI 8.8–28.4). The overall pooled prevalence of ADHD was observed as 63.2 (95% CI 49.2–77.1) in 1000 children surveyed. Significant heterogeneity was observed in the systemic review. Conclusions ADHD accounts for a significant health burden, and understanding its burden is crucial for effective health policy-making for educational intervention and rehabilitation.
- 16 January 2022
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 89 (6) , 570-578
Burden of Attention Deficit Hyperactivity Disorder (ADHD) in Indian Children: A Systematic Review and Meta-Analysis
Objective To determine the pooled prevalence of attention deficit hyperactivity disorder (ADHD) in Indian children. Methods The searching of published literature was conducted in different databases (PubMed, Ovid SP, and EMBASE). The authors also tried to acquire information from the unpublished literature about the prevalence of ADHD. A screening was done to include eligible original studies, community or school-based, cross-sectional or cohort, reporting the prevalence of ADHD in children aged ≤ 18 y in India. Retrieved data were analyzed using STATA MP12 (Texas College station). Results Of 729 studies retrieved by searching different databases, 183 studies were removed as duplicates, and 546 titles and abstracts were screened. After screening, 19 studies were included for quantitative analysis. Subgroup analysis was conducted with respect to their setting (school-based/community-based). Fifteen studies performed in a school-based setting showed 75.1 (95% CI 56.0–94.1) pooled prevalence of ADHD per 1000 children of 4–19 y of age. In community-based settings, the pooled prevalence per 1000 children surveyed was 18.6 (95% CI 8.8–28.4). The overall pooled prevalence of ADHD was observed as 63.2 (95% CI 49.2–77.1) in 1000 children surveyed. Significant heterogeneity was observed in the systemic review. Conclusions ADHD accounts for a significant health burden, and understanding its burden is crucial for effective health policy-making for educational intervention and rehabilitation.
Global epidemiological burden of fungal infections in cirrhosis patients: A systematic review with meta‐analysis
Background and Aims: Fungal infections (FIs) have serious implications, yet understated in cirrhosis. Therefore, we reviewed the epidemiology and trends of FIs among cirrhotics.Methods: Four electronic databases were searched for full‐text articles describing prevalence of FIs in cirrhosis. Studies from post‐transplant, malignancy and classical‐immuno‐deficiency patients were excluded. A random‐effects meta‐analysis was done to pool estimates of FIs (overall, and by type and infection‐site), and their variation(I2) was explored on moderator‐analysis and meta‐regression. Risk of bias and asymmetry in estimates was assessed by a checklist and Egger's regression, respectively.(CRD42019142782).Results: Thirty‐four low‐risk and four moderate‐risk studies (31 984 cirrhotics) were included. Pooled estimates of overall FIs (17 studies), invasive fungal infections (IFIs; 17 studies), invasive candidiasis (23 studies) and invasive aspergillosis (16 studies) in cirrhosis were 10.2%(6.0‐16.9), 9.5%(5.4‐16.2), 4.0%(2.0‐8.0) and 2.8%(1.5‐5.3), respectively (I2 > 90%;each). Site of FIs in decreasing order of pooled prevalence was pulmonary, urinary tract, bloodstream, peritoneal, oesophageal and cerebral. Geographic differences in these estimates were remarkable, with highest burden of overall FIs from Belgium, the United States and India. Non‐albicans‐Candida and Aspergillus infections have increased over the last decade in cirrhosis. Intensive‐care‐unit (ICU)‐admitted and acute‐on‐chronic liver failure (ACLF) patients had the highest prevalence of IFIs. MELD score(cases), bias score and sample size across studies were the predictors of variance in overall FI estimates. Diabetes, steroid and broad‐spectrum antibiotic‐exposure, and multiple organ failures were the common predispositions reported in patients with FIs.Conclusions: FIs impose a substantial burden in cirrhosis. ACLF and ICU admission should be considered as a host factor for defining IFIs. Epidemiology of FIs can guide interpretation of biomarkers and antifungal treatment in cirrhosis.
Global epidemiological burden of fungal infections in cirrhosis patients: A systematic review with meta‐analysis
Background and Aims: Fungal infections (FIs) have serious implications, yet understated in cirrhosis. Therefore, we reviewed the epidemiology and trends of FIs among cirrhotics.Methods: Four electronic databases were searched for full‐text articles describing prevalence of FIs in cirrhosis. Studies from post‐transplant, malignancy and classical‐immuno‐deficiency patients were excluded. A random‐effects meta‐analysis was done to pool estimates of FIs (overall, and by type and infection‐site), and their variation(I2) was explored on moderator‐analysis and meta‐regression. Risk of bias and asymmetry in estimates was assessed by a checklist and Egger's regression, respectively.(CRD42019142782).Results: Thirty‐four low‐risk and four moderate‐risk studies (31 984 cirrhotics) were included. Pooled estimates of overall FIs (17 studies), invasive fungal infections (IFIs; 17 studies), invasive candidiasis (23 studies) and invasive aspergillosis (16 studies) in cirrhosis were 10.2%(6.0‐16.9), 9.5%(5.4‐16.2), 4.0%(2.0‐8.0) and 2.8%(1.5‐5.3), respectively (I2 > 90%;each). Site of FIs in decreasing order of pooled prevalence was pulmonary, urinary tract, bloodstream, peritoneal, oesophageal and cerebral. Geographic differences in these estimates were remarkable, with highest burden of overall FIs from Belgium, the United States and India. Non‐albicans‐Candida and Aspergillus infections have increased over the last decade in cirrhosis. Intensive‐care‐unit (ICU)‐admitted and acute‐on‐chronic liver failure (ACLF) patients had the highest prevalence of IFIs. MELD score(cases), bias score and sample size across studies were the predictors of variance in overall FI estimates. Diabetes, steroid and broad‐spectrum antibiotic‐exposure, and multiple organ failures were the common predispositions reported in patients with FIs.Conclusions: FIs impose a substantial burden in cirrhosis. ACLF and ICU admission should be considered as a host factor for defining IFIs. Epidemiology of FIs can guide interpretation of biomarkers and antifungal treatment in cirrhosis.
- 23 August 2021
- Published by Wiley in Pediatric Pulmonology
- Vol. 56 (10) , 3189-3199
Paracetamol exposure and asthma: What does the evidence say? An overview of systematic reviews
Objective: To conduct an umbrella review collating the existing evidence to determine whether there is an association between exposure of Paracetamol in‐utero or in infancy and the development of childhood Asthma.Methods: In this review, systematic reviews with or without meta‐analysis that reported the association between paracetamol and asthma in children were included. To identify relevant reviews, a search was performed in the electronic databases PubMed, the Cochrane Library, and Ovid MEDLINE. The protocol was registered in PROSPERO CRD42020156023. A separate search was conducted for primary studies from the last 5 years not yet included in systematic reviews reporting the association from January 2016 to March 2021.Results: The electronic searches identified 1966 review titles. After the removal of 493 duplicates, 1475 titles and abstracts were screened against the eligibility criteria. Full‐text screening yielded six systematic reviews to be included in this review. The search for primary studies in the last 5 years yielded 1214 hits, out of which 5 studies were found suitable for inclusion. Three of them, that were not included in the systematic reviews, and have been summarised in this paper. The odds ratios (ORs) for the outcome of asthma in offspring of mothers with prenatal paracetamol consumption in any trimester were 1.28 (1.13–1.39) and 1.21 (1.02–1.44). For first trimester exposures, they were 1.12 (0.99–1.27), 1.39 (1.01–1.91), and 1.21 (1.14–1.28), for the second or third trimester, they were 1.49 (1.37–1.63) and 1.13 (1.04–1.23). For the third trimester only, the figure was 1.17 (1.04–1.31). Of the six reviews included, 1 had a low risk of bias, 2 had an unclear risk while 3 had a high risk of bias assessed using the ROBIS tool. There was no significant increased risk of asthma with early infancy exposure. The inter‐study heterogeneity varied from I2 = 41% to I2 = 76% across reviews. In the primary studies, the OR for prenatal exposure ranged from 1.12 (0.25–4.98) to 4.66 (1.92–11.3) and for infancy exposure was 1.56 (1.06–2.30). All three included primary studies were adjudged to be of high quality using the Newcastle Ottawa scale.Conclusions: There is a modest association between paracetamol exposure in‐utero and the future development of asthma. Exposure in infancy has a less consistant association. All the studies done thus far are observational in nature, with their inherent biases. Further research, preferably randomized controlled trials are recommended to answer this pertinent question.
- 23 August 2021
- Published by Wiley in Pediatric Pulmonology
- Vol. 56 (10) , 3189-3199
Paracetamol exposure and asthma: What does the evidence say? An overview of systematic reviews
Objective: To conduct an umbrella review collating the existing evidence to determine whether there is an association between exposure of Paracetamol in‐utero or in infancy and the development of childhood Asthma.Methods: In this review, systematic reviews with or without meta‐analysis that reported the association between paracetamol and asthma in children were included. To identify relevant reviews, a search was performed in the electronic databases PubMed, the Cochrane Library, and Ovid MEDLINE. The protocol was registered in PROSPERO CRD42020156023. A separate search was conducted for primary studies from the last 5 years not yet included in systematic reviews reporting the association from January 2016 to March 2021.Results: The electronic searches identified 1966 review titles. After the removal of 493 duplicates, 1475 titles and abstracts were screened against the eligibility criteria. Full‐text screening yielded six systematic reviews to be included in this review. The search for primary studies in the last 5 years yielded 1214 hits, out of which 5 studies were found suitable for inclusion. Three of them, that were not included in the systematic reviews, and have been summarised in this paper. The odds ratios (ORs) for the outcome of asthma in offspring of mothers with prenatal paracetamol consumption in any trimester were 1.28 (1.13–1.39) and 1.21 (1.02–1.44). For first trimester exposures, they were 1.12 (0.99–1.27), 1.39 (1.01–1.91), and 1.21 (1.14–1.28), for the second or third trimester, they were 1.49 (1.37–1.63) and 1.13 (1.04–1.23). For the third trimester only, the figure was 1.17 (1.04–1.31). Of the six reviews included, 1 had a low risk of bias, 2 had an unclear risk while 3 had a high risk of bias assessed using the ROBIS tool. There was no significant increased risk of asthma with early infancy exposure. The inter‐study heterogeneity varied from I2 = 41% to I2 = 76% across reviews. In the primary studies, the OR for prenatal exposure ranged from 1.12 (0.25–4.98) to 4.66 (1.92–11.3) and for infancy exposure was 1.56 (1.06–2.30). All three included primary studies were adjudged to be of high quality using the Newcastle Ottawa scale.Conclusions: There is a modest association between paracetamol exposure in‐utero and the future development of asthma. Exposure in infancy has a less consistant association. All the studies done thus far are observational in nature, with their inherent biases. Further research, preferably randomized controlled trials are recommended to answer this pertinent question.
- 9 January 2020
- Published by Springer Nature in Lung
- Vol. 198 (2) , 377-383
Association of Serum TGF-β1 Levels with Different Clinical Phenotypes of Cystic Fibrosis Exacerbation
Purpose Cystic Fibrosis (CF) is a multi-organ genetic disorder and Transforming Growth Factor (TGF-β1) is a modifier gene which modulates lung pathology in CF. There is great phenotypic variability among CF patients who even have similar genotype. The aim of the present study was to associate the serum levels of TGF-β1 with several clinical phenotypes of CF. Methods The diagnosed cases of CF were recruited and the blood sample was withdrawn at different time points: during exacerbation (n = 26), non-exacerbation (n = 9) and after antibiotic therapy (n = 11). The concentration of the total TGF-β1 in serum was measured with commercial ELISA kit. The ΔF508 mutation was assessed by the Amplification Refractory Mutation System (ARMS-PCR). Results The levels of TGF-β1 were increased in exacerbation phase (119.89 ± 29.64 ng/mL), infection with P. aeruginosa (121.8 ± 28.83 ng/mL) and in subjects with ΔF508 mutation (139.2 ± 19.59 ng/mL). The levels of TGF-β1 in CF patients with Allergic Bronchopulmonary Aspergillosis (ABPA) (109.97 ± 27.71 ng/mL) were decreased as compared to CF patients without ABPA (123.55 ± 30.20 ng/mL). It was observed that the serum levels of TGF-β1 were decreased significantly after antibiotic therapy (p < 0.05). Conclusions The present study has determined that the serum levels of TGF-β1 vary with the type of infections, ΔF508 CFTR mutation, presence of ABPA and response to therapy.
- 9 January 2020
- Published by Springer Nature in Lung
- Vol. 198 (2) , 377-383
Association of Serum TGF-β1 Levels with Different Clinical Phenotypes of Cystic Fibrosis Exacerbation
Purpose Cystic Fibrosis (CF) is a multi-organ genetic disorder and Transforming Growth Factor (TGF-β1) is a modifier gene which modulates lung pathology in CF. There is great phenotypic variability among CF patients who even have similar genotype. The aim of the present study was to associate the serum levels of TGF-β1 with several clinical phenotypes of CF. Methods The diagnosed cases of CF were recruited and the blood sample was withdrawn at different time points: during exacerbation (n = 26), non-exacerbation (n = 9) and after antibiotic therapy (n = 11). The concentration of the total TGF-β1 in serum was measured with commercial ELISA kit. The ΔF508 mutation was assessed by the Amplification Refractory Mutation System (ARMS-PCR). Results The levels of TGF-β1 were increased in exacerbation phase (119.89 ± 29.64 ng/mL), infection with P. aeruginosa (121.8 ± 28.83 ng/mL) and in subjects with ΔF508 mutation (139.2 ± 19.59 ng/mL). The levels of TGF-β1 in CF patients with Allergic Bronchopulmonary Aspergillosis (ABPA) (109.97 ± 27.71 ng/mL) were decreased as compared to CF patients without ABPA (123.55 ± 30.20 ng/mL). It was observed that the serum levels of TGF-β1 were decreased significantly after antibiotic therapy (p < 0.05). Conclusions The present study has determined that the serum levels of TGF-β1 vary with the type of infections, ΔF508 CFTR mutation, presence of ABPA and response to therapy.
- 19 December 2019
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 12 (12) , CD011780
Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis
Background Poliomyelitis is a debilitating and deadly infection. Despite exponential growth in medical science, there is still no cure for the disease, which is caused by three types of wild polioviruses: types 1, 2, and 3. According to the Global Polio Eradication Initiative (GPEI), wild poliovirus is still in circulation in three countries, and fresh cases have been reported even in the year 2018. Due to the administration of live vaccines, the risk for vaccine‐derived poliovirus (VDPV) is high in areas that are free from wild polioviruses. This is evident based on the fact that VDPV caused 20 outbreaks between 2000 and 2011. Recent recommendations from the World Health Organization favoured the inclusion of inactivated poliovirus vaccine (IPV) in the global immunisation schedule. IPV can be delivered in two ways: intramuscularly and intradermally. IPV was previously administered intramuscularly, but shortages in vaccine supplies, coupled with the higher costs of the vaccines, led to the innovation of delivering a fractional dose (one‐fifth) of IPV intradermally. However, there is uncertainty regarding the efficacy, immunogenicity, and safety of an intradermal, fractional dose of IPV compared to an intramuscular, full dose of IPV. Objectives To compare the immunogenicity and efficacy of an inactivated poliovirus vaccine (IPV) in equivalent immunisation schedules using fractional‐dose IPV given via the intradermal route versus full‐dose IPV given via the intramuscular route. Search methods We searched CENTRAL, MEDLINE, Embase, 10 other databases, and two trial registers up to February 2019. We also searched the GPEI website and scanned the bibliographies of key studies and reviews in order to identify any additional published and unpublished trials in this area not captured by our electronic searches. Selection criteria Randomised controlled trials (RCTs) and quasi‐RCTs of healthy individuals of any age who are eligible for immunisation with IPV, comparing intradermal fractional‐dose (one‐fifth) IPV to intramuscular full‐dose IPV. Data collection and analysis We used standard methodological procedures expected by Cochrane. Main results We included 13 RCTs involving a total of 7292 participants, both children (n = 6402) and adults (n = 890). Nine studies were conducted in middle‐income countries, three studies in high‐income countries, and only one study in a low‐income country. Five studies did not report methods of randomisation, and one study failed to conceal the allocations. Eleven studies did not blind participants, and six studies did not blind outcome assessments. Two studies had high attrition rates, and one study selectively reported the results. Three studies were funded by pharmaceutical companies. Paralytic poliomyelitis. No study reported data on this outcome. Seroconversion rates. These were significantly higher for all three types of wild poliovirus for children given intramuscular full‐dose IPV after a single primary dose and two primary doses, but only significantly higher for type two wild poliovirus given intramuscularly after three primary doses: • dose one (six studies): poliovirus type 1 (odds ratio (OR) 0.30, 95% confidence interval (CI) 0.22 to 0.41; 2570 children); poliovirus type 2 (OR 0.43, 95% CI 0.31 to 0.60; 2567 children); poliovirus type 3 (OR 0.19, 95% CI 0.12 to 0.30; 2571 children); • dose two (three studies): poliovirus type 1 (OR 0.23, 95% CI 0.16 to 0.33; 981 children); poliovirus type 2 (OR 0.41, 95% CI 0.28 to 0.60; 853 children); and poliovirus type 3 (OR 0.12, 95% CI 0.07 to 0.22; 855 children); and • dose three (three studies): poliovirus type 1 (OR 0.45, 95% CI 0.07 to 3.15; 973 children); poliovirus type 2 (OR 0.34, 95% CI 0.19 to 0.63; 973 children); and poliovirus type 3 (OR 0.18, 95% CI 0.01 to 2.58; 973 children). Using the GRADE approach, we rated the certainty of the evidence as low or very low for seroconversion rate (after a single, two, or three primary doses) for all three poliovirus types due to significant risk of bias, heterogeneity, and indirectness in applicability/generalisability. Geometric mean titres. No study reported mean antibody titres. Median antibody titres were higher for intramuscular full‐dose IPV (7 studies with 4887 children); although these studies also reported a rise in antibody titres in the intradermal group, none reported the duration for which the titres remained high. Any vaccine‐related adverse event. Five studies (2217 children) reported more adverse events, such as fever and redness, in the intradermal group, whilst two studies (1904 children) reported more adverse events in the intramuscular group. Authors' conclusions There is low‐ and very low‐certainty evidence that intramuscular full‐dose IPV may result in a slight increase in seroconversion rates for all three types of wild poliovirus, compared with intradermal fractional‐dose IPV. We are uncertain whether intradermal fractional‐dose (one‐fifth) IPV has better protective effects and causes fewer adverse events in children than intramuscular full‐dose IPV.
- 19 December 2019
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 12 (12) , CD011780
Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis
Background Poliomyelitis is a debilitating and deadly infection. Despite exponential growth in medical science, there is still no cure for the disease, which is caused by three types of wild polioviruses: types 1, 2, and 3. According to the Global Polio Eradication Initiative (GPEI), wild poliovirus is still in circulation in three countries, and fresh cases have been reported even in the year 2018. Due to the administration of live vaccines, the risk for vaccine‐derived poliovirus (VDPV) is high in areas that are free from wild polioviruses. This is evident based on the fact that VDPV caused 20 outbreaks between 2000 and 2011. Recent recommendations from the World Health Organization favoured the inclusion of inactivated poliovirus vaccine (IPV) in the global immunisation schedule. IPV can be delivered in two ways: intramuscularly and intradermally. IPV was previously administered intramuscularly, but shortages in vaccine supplies, coupled with the higher costs of the vaccines, led to the innovation of delivering a fractional dose (one‐fifth) of IPV intradermally. However, there is uncertainty regarding the efficacy, immunogenicity, and safety of an intradermal, fractional dose of IPV compared to an intramuscular, full dose of IPV. Objectives To compare the immunogenicity and efficacy of an inactivated poliovirus vaccine (IPV) in equivalent immunisation schedules using fractional‐dose IPV given via the intradermal route versus full‐dose IPV given via the intramuscular route. Search methods We searched CENTRAL, MEDLINE, Embase, 10 other databases, and two trial registers up to February 2019. We also searched the GPEI website and scanned the bibliographies of key studies and reviews in order to identify any additional published and unpublished trials in this area not captured by our electronic searches. Selection criteria Randomised controlled trials (RCTs) and quasi‐RCTs of healthy individuals of any age who are eligible for immunisation with IPV, comparing intradermal fractional‐dose (one‐fifth) IPV to intramuscular full‐dose IPV. Data collection and analysis We used standard methodological procedures expected by Cochrane. Main results We included 13 RCTs involving a total of 7292 participants, both children (n = 6402) and adults (n = 890). Nine studies were conducted in middle‐income countries, three studies in high‐income countries, and only one study in a low‐income country. Five studies did not report methods of randomisation, and one study failed to conceal the allocations. Eleven studies did not blind participants, and six studies did not blind outcome assessments. Two studies had high attrition rates, and one study selectively reported the results. Three studies were funded by pharmaceutical companies. Paralytic poliomyelitis. No study reported data on this outcome. Seroconversion rates. These were significantly higher for all three types of wild poliovirus for children given intramuscular full‐dose IPV after a single primary dose and two primary doses, but only significantly higher for type two wild poliovirus given intramuscularly after three primary doses: • dose one (six studies): poliovirus type 1 (odds ratio (OR) 0.30, 95% confidence interval (CI) 0.22 to 0.41; 2570 children); poliovirus type 2 (OR 0.43, 95% CI 0.31 to 0.60; 2567 children); poliovirus type 3 (OR 0.19, 95% CI 0.12 to 0.30; 2571 children); • dose two (three studies): poliovirus type 1 (OR 0.23, 95% CI 0.16 to 0.33; 981 children); poliovirus type 2 (OR 0.41, 95% CI 0.28 to 0.60; 853 children); and poliovirus type 3 (OR 0.12, 95% CI 0.07 to 0.22; 855 children); and • dose three (three studies): poliovirus type 1 (OR 0.45, 95% CI 0.07 to 3.15; 973 children); poliovirus type 2 (OR 0.34, 95% CI 0.19 to 0.63; 973 children); and poliovirus type 3 (OR 0.18, 95% CI 0.01 to 2.58; 973 children). Using the GRADE approach, we rated the certainty of the evidence as low or very low for seroconversion rate (after a single, two, or three primary doses) for all three poliovirus types due to significant risk of bias, heterogeneity, and indirectness in applicability/generalisability. Geometric mean titres. No study reported mean antibody titres. Median antibody titres were higher for intramuscular full‐dose IPV (7 studies with 4887 children); although these studies also reported a rise in antibody titres in the intradermal group, none reported the duration for which the titres remained high. Any vaccine‐related adverse event. Five studies (2217 children) reported more adverse events, such as fever and redness, in the intradermal group, whilst two studies (1904 children) reported more adverse events in the intramuscular group. Authors' conclusions There is low‐ and very low‐certainty evidence that intramuscular full‐dose IPV may result in a slight increase in seroconversion rates for all three types of wild poliovirus, compared with intradermal fractional‐dose IPV. We are uncertain whether intradermal fractional‐dose (one‐fifth) IPV has better protective effects and causes fewer adverse events in children than intramuscular full‐dose IPV.
- 18 November 2019
- Published by Georg Thieme Verlag KG in Journal of Pediatric Intensive Care
- Vol. 09 (01) , 001-011
Time of Pediatric Intensive Care Unit Admission and Mortality: A Systematic Review and Meta-Analysis
The aim of this study was to determine the association between the time of admission (day, night, and/or weekends) and mortality among critically ill children admitted to a pediatric intensive care unit (PICU). Electronic databases that were searched include PubMed, Embase, Web of Science, CINAHL (Cumulative Index of Nursing and Allied Health Literature), Ovid, and Cochrane Library since inception till June 15, 2018. The article included observational studies reporting inhospital mortality and the time of admission to PICU limited to patients aged younger than 18 years. Meta-analysis was performed by a frequentist approach with both fixed and random effect models. The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach was used to evaluate the quality of evidence. Ten studies met our inclusion criteria. Five studies comparing weekday with weekend admissions showed better odds of survival on weekdays (odds ratio [OR]: 0.77; 95% confidence interval [CI]: 0.60–0.99). Pooled data of four studies showed that odds of mortality were similar between day and night admissions (OR: 0.93; 95% CI: 0.77–1.13). Similarly, three studies comparing admission during off-hours versus regular hours did not show better odds of survival during regular hours (OR: 0.77; 95% CI: 0.57–1.05). Heterogeneity was significant due to variable sample sizes and time period. Inconsistency in adjusting for confounders across the included studies precluded us from analyzing the adjusted risk of mortality. Weekday admissions to PICU were associated with lesser odds of mortality. No significant differences in the odds of mortality were found between admissions during day versus night or between admission during regular hours and that during off-hours. However, the evidence is of low quality and requires larger prospective studies.
- 18 November 2019
- Published by Georg Thieme Verlag KG in Journal of Pediatric Intensive Care
- Vol. 09 (01) , 001-011
Time of Pediatric Intensive Care Unit Admission and Mortality: A Systematic Review and Meta-Analysis
The aim of this study was to determine the association between the time of admission (day, night, and/or weekends) and mortality among critically ill children admitted to a pediatric intensive care unit (PICU). Electronic databases that were searched include PubMed, Embase, Web of Science, CINAHL (Cumulative Index of Nursing and Allied Health Literature), Ovid, and Cochrane Library since inception till June 15, 2018. The article included observational studies reporting inhospital mortality and the time of admission to PICU limited to patients aged younger than 18 years. Meta-analysis was performed by a frequentist approach with both fixed and random effect models. The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach was used to evaluate the quality of evidence. Ten studies met our inclusion criteria. Five studies comparing weekday with weekend admissions showed better odds of survival on weekdays (odds ratio [OR]: 0.77; 95% confidence interval [CI]: 0.60–0.99). Pooled data of four studies showed that odds of mortality were similar between day and night admissions (OR: 0.93; 95% CI: 0.77–1.13). Similarly, three studies comparing admission during off-hours versus regular hours did not show better odds of survival during regular hours (OR: 0.77; 95% CI: 0.57–1.05). Heterogeneity was significant due to variable sample sizes and time period. Inconsistency in adjusting for confounders across the included studies precluded us from analyzing the adjusted risk of mortality. Weekday admissions to PICU were associated with lesser odds of mortality. No significant differences in the odds of mortality were found between admissions during day versus night or between admission during regular hours and that during off-hours. However, the evidence is of low quality and requires larger prospective studies.
- 13 July 2019
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 86 (12) , 1124-1130
Prevalence of Cerebral Palsy in Indian Children: A Systematic Review and Meta-Analysis
To determine the pooled-prevalence of cerebral palsy in Indian children. The authors searched the published literature from different databases (PubMed, Ovid SP and EMBASE) and also tried to acquire information from the unpublished literature about the prevalence of cerebral palsy. They screened prospective/retrospective, cross-sectional, and cohort studies of children with cerebral palsy in the Indian population. Data were extracted from the included studies, and quality assessment was performed. Data were analysed using STATA MP12 (Texas, College Station). Of the 862 publications searched, eight studies were qualified and included for quantitative analysis. The overall pooled prevalence of cerebral palsy per 1000 children surveyed was 2.95 (95% CI 2.03-3.88). Sub-group analysis for rural, urban and mixed rural-urban study population demonstrated the pooled prevalence as 1.83 (95% CI 0.41-3.25), 2.29 (95% CI 1.43-3.16) and 4.37 (95% CI 2.24-6.51) respectively. This systematic review observed a paucity of high-quality, prevalence studies of cerebral palsy in India, which is a limitation to estimate the inferences for a national estimate. The observed prevalence of cerebral palsy in India is near similar to global estimates. There is a need to re-allocate resources and revisit the implementation of the existing policies for the prevention and management of cerebral palsy, taking into account the current disease burden.
- 13 July 2019
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 86 (12) , 1124-1130
Prevalence of Cerebral Palsy in Indian Children: A Systematic Review and Meta-Analysis
To determine the pooled-prevalence of cerebral palsy in Indian children. The authors searched the published literature from different databases (PubMed, Ovid SP and EMBASE) and also tried to acquire information from the unpublished literature about the prevalence of cerebral palsy. They screened prospective/retrospective, cross-sectional, and cohort studies of children with cerebral palsy in the Indian population. Data were extracted from the included studies, and quality assessment was performed. Data were analysed using STATA MP12 (Texas, College Station). Of the 862 publications searched, eight studies were qualified and included for quantitative analysis. The overall pooled prevalence of cerebral palsy per 1000 children surveyed was 2.95 (95% CI 2.03-3.88). Sub-group analysis for rural, urban and mixed rural-urban study population demonstrated the pooled prevalence as 1.83 (95% CI 0.41-3.25), 2.29 (95% CI 1.43-3.16) and 4.37 (95% CI 2.24-6.51) respectively. This systematic review observed a paucity of high-quality, prevalence studies of cerebral palsy in India, which is a limitation to estimate the inferences for a national estimate. The observed prevalence of cerebral palsy in India is near similar to global estimates. There is a need to re-allocate resources and revisit the implementation of the existing policies for the prevention and management of cerebral palsy, taking into account the current disease burden.
Need to re‐look cut‐off of Aspergillus‐specific IgE levels in children with ABPA
Summary: The cut‐offs for total and specific IgE used for diagnosing ABPA in children have been adopted from adult literature and have not been validated in the paediatric population. To establish the ideal cut‐offs of total IgE and Aspergillus‐specific IgE for the diagnosis of ABPA in children. This study was a prospective observational case‐control study, conducted in a tertiary care hospital in North India, enrolling 140 children with partly controlled and uncontrolled asthma. Seventy children had ABPA based on the Rosenberg‐Patterson Criteria (Cases) whereas 70 children were without ABPA (Controls). All children were subjected to clinical examination and investigations such as absolute eosinophil count, total IgE, Aspergillus‐specific IgE, Aspergillus skin prick test and radiological tests. ROC curve analysis was done to determine the ideal cut‐offs of total and specific IgE to diagnose ABPA. The ROC curve analysis determined 1204IU/L as the cut‐off value of total IgE with a sensitivity of 79.7% (95%CI 68.31% to 88.44%) and specificity of 53.1% (95%CI 40.23 to 65.7). The ROC analysis of specific IgE levels of children with ABPA determined the cut‐off value of 0.49 KAU/L with a sensitivity of 94.03% (95%CI 85.41 to 98.35) and specificity of 88.89% (95%CI 75.94% to 96.29%). We propose that the cut‐offs of total and specific IgE need to be relooked in the paediatric population. Cut‐offs of total IgE as 1204 IU/L and for Aspergillus‐specific IgE as 0.49KAU/L seem appropriate. Large multicentric studies should be conducted to determine the ideal values for diagnosing paediatric ABPA.
Need to re‐look cut‐off of Aspergillus‐specific IgE levels in children with ABPA
Summary: The cut‐offs for total and specific IgE used for diagnosing ABPA in children have been adopted from adult literature and have not been validated in the paediatric population. To establish the ideal cut‐offs of total IgE and Aspergillus‐specific IgE for the diagnosis of ABPA in children. This study was a prospective observational case‐control study, conducted in a tertiary care hospital in North India, enrolling 140 children with partly controlled and uncontrolled asthma. Seventy children had ABPA based on the Rosenberg‐Patterson Criteria (Cases) whereas 70 children were without ABPA (Controls). All children were subjected to clinical examination and investigations such as absolute eosinophil count, total IgE, Aspergillus‐specific IgE, Aspergillus skin prick test and radiological tests. ROC curve analysis was done to determine the ideal cut‐offs of total and specific IgE to diagnose ABPA. The ROC curve analysis determined 1204IU/L as the cut‐off value of total IgE with a sensitivity of 79.7% (95%CI 68.31% to 88.44%) and specificity of 53.1% (95%CI 40.23 to 65.7). The ROC analysis of specific IgE levels of children with ABPA determined the cut‐off value of 0.49 KAU/L with a sensitivity of 94.03% (95%CI 85.41 to 98.35) and specificity of 88.89% (95%CI 75.94% to 96.29%). We propose that the cut‐offs of total and specific IgE need to be relooked in the paediatric population. Cut‐offs of total IgE as 1204 IU/L and for Aspergillus‐specific IgE as 0.49KAU/L seem appropriate. Large multicentric studies should be conducted to determine the ideal values for diagnosing paediatric ABPA.